ACTIVE_NOT_RECRUITING

A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Talk to us

Conditions

Hidradenitis Suppurativa

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development. The study will last approximately 62 weeks and may include up to 31 visits.

Official Title

A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Eltrekibart in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Quick Facts

Study Start:2023-10-23
Study Completion:2026-07
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:ACTIVE_NOT_RECRUITING

Study ID

NCT06046729

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 75 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Have a diagnosis of HS for at least 12 months.
  2. * Have HS lesions in at least 2 distinct anatomical regions. At least 1 of the lesions must be at least Hurley Stage II or III.
  3. * Have an (abscess plus inflammatory nodule) count of at least 5.
  4. * Agree to use topical antiseptics daily.
  5. * Had an inadequate response or intolerance to a 28-day course of oral antibiotics.
  1. * Have more than 20 draining fistulae.
  2. * Have had surgical treatment for HS in the last 4 weeks before randomization.
  3. * Have an active skin disease or condition, that could interfere with the assessment of HS.
  4. * Have a current or recent acute, active infection.
  5. * Are immunocompromised.
  6. * Have a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse within 1 year before screening.

Contacts and Locations

Principal Investigator

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
STUDY_DIRECTOR
Eli Lilly and Company

Study Locations (Sites)

Medical Dermatology Specialists
Phoenix, Arizona, 85006
United States
Saguaro Dermatology Associates, LLC - Probity - PPDS
Phoenix, Arizona, 85008
United States
Arkansas Research Trials, LLC
North Little Rock, Arkansas, 72117
United States
Northwest Arkansas Clinical Trials Center
Rogers, Arkansas, 72758
United States
First OC Dermatology Research Inc
Fountain Valley, California, 92708
United States
Center For Dermatology Clinical Research, Inc.
Fremont, California, 94538
United States
Dermatology Research Associates
Los Angeles, California, 90045
United States
Dermatology Institute and Skin Care Center
Santa Monica, California, 90404
United States
University of Connecticut
Farmington, Connecticut, 06032
United States
Direct Helpers Research Center
Hialeah, Florida, 33012
United States
University of Miami
Miami, Florida, 33125
United States
Skin Research of South Florida
Miami, Florida, 33173-1407
United States
ForCare Clinical Research
Tampa, Florida, 33613-1244
United States
Alliance Clinical Research of Tampa
Tampa, Florida, 33615
United States
Olympian Clinical Research
Tampa, Florida, 33615
United States
Advanced Medical Research, PC
Sandy Springs, Georgia, 30328
United States
NorthShore Medical Group Dermatology - Skokie
Skokie, Illinois, 60077-1049
United States
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana, 46250
United States
Equity Medical - Bowling Green
Bowling Green, Kentucky, 42104
United States
Derm Research LLC
Louisville, Kentucky, 40217
United States
Care Access-Marriottsville
Marriottsville, Maryland, 21104
United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215
United States
Revival Research Institute - Troy
Troy, Michigan, 48084
United States
Washington University School of Medicine
Saint Louis, Missouri, 63110
United States
Skin Specialists, P.C
Omaha, Nebraska, 68144
United States
ActivMed Practices & Research, Inc.
Portsmouth, New Hampshire, 03801
United States
Darst Dermatology
Charlotte, North Carolina, 28277-8014
United States
Dermatology Specialists of Charlotte
Charlotte, North Carolina, 28277
United States
Duke University Medical Center
Durham, North Carolina, 27710-3038
United States
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106
United States
Apex Clinical Research Center
Mayfield Heights, Ohio, 44124
United States
DermDox Centers for Dermatology
Camp Hill, Pennsylvania, 17011
United States
DermDox Dermatology Centers
Sugarloaf, Pennsylvania, 18249
United States
Medical University of South Carolina
Charleston, South Carolina, 29425
United States
Columbia Dermatology & Aesthetics
Columbia, South Carolina, 29212-8623
United States
International Clinical Research - Tennessee (IC Research)
Murfreesboro, Tennessee, 37130
United States
Advanced Research Experts
Nashville, Tennessee, 37211
United States
Modern Research Associates
Dallas, Texas, 75231
United States
North Texas Clinical Research
Frisco, Texas, 75034
United States
Jordan Valley Dermatology Center
South Jordan, Utah, 84095
United States
Dermatology Specialists of Spokane
Spokane, Washington, 99202-1332
United States
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
United States

Collaborators and Investigators

Sponsor: Eli Lilly and Company

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), STUDY_DIRECTOR, Eli Lilly and Company

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-10-23
Study Completion Date2026-07

Study Record Updates

Study Start Date2023-10-23
Study Completion Date2026-07

Terms related to this study

Additional Relevant MeSH Terms

  • Hidradenitis Suppurativa